- 作者: Tsu-Yi Chao; Ching-Liang Ho; Su-Huei Lee; Mary Mei-Ju Chen; Anthony Janckila; Lung T. Yam
- 作者服務機構: Division of Hermatology/Oncology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC; Division of Hematology, Veterans Administrative Medical Center, Louisville, Ky., USA
- 中文摘要: --
- 英文摘要: Diagnosis and follow-up of bone metastases in breastcancer patients usually rely on symptoms and imagingstudies. Tartrate-resistant acid phosphatase 5b (TRACP5b) is a specific marker of osteoclasts and is herein pro-posed as a marker of bone metastasis in breast cancerpatients. An immunoassay using a monoclonal anti-body, 1466, was used to measure the activity of serumTRACP 5b at pH 6.1 in 30 early breast cancer patientswithout bone metastasis and in 30 aged-matched breastcancer patients with bone metastasis. Another 60 normalvolunteers were recruited as controls. Bone alkalinephosphatase (BAP), a traditional marker of bone turn-over, was also measured in selected cases. The overallmean TRACP 5b activity in normal women was 2.83±1.1 U/I; and it increased with age. The mean TRACP 5bactivity in early breast cancer patients did not differ fromthat of the normal group(2.93±0.64 vs. 2.83±1.1 U/I;p=0.66), whereas it was significantly higher in breastcancer patients with bone metastasis(5.42±2.5 vs, 2.83士1.1 U/I; p<0.0001). BAP activity was significantly high-er in breast cancer patients with bone metastasis than inearly breast cancer patients (p=0.004).Serum TRACP 5bactivity correlated well with BAP activity in breast cancerpatients with bone metastasis (p<0.0001), but not in nor-mal individuals or in patients without bone metastasis.TRACP 5b activity can be considered a surrogate indica-for of bone metastasis in breast cancer patients.
- 中文關鍵字: --
- 英文關鍵字: --